DND-41 In Vitro High Content Screening (HCS) Assay

This assay is to provide DND-41-based In Vitro High Content Screening (HCS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

DND-41

Human

DND-41 was established from the peripheral blood of 13-year-old boy with T-acute lymphoblastic leukemia (T-ALL; type III cortical) in 1977; described to carry CDKN2B (p15INK4B) and CDKN2A (p16INK4A) deletions and TP53 (p53)mutation.

Acute Lymphoblastic Leukemia; ALL

Oncology

In Vitro High Content Screening (HCS) Assay

DND-41-cell based In Vitro High Content Screening (HCS) Assay

HCS is one of the latest techniques used in cancer drug discovery programs. Unlike traditional HTS platforms, HCS provides more visual information about the experiment being conducted. HCS is a very powerful tool for multivariate and quantitative data analysis. Cellbased HCS systems have also gained much attention in biological research and cancer drug discovery programs.

High-throughput Screening, High Content Screening and Reporter Gene Assays